Literature DB >> 7894497

CYP3A gene expression in human gut epithelium.

J C Kolars1, K S Lown, P Schmiedlin-Ren, M Ghosh, C Fang, S A Wrighton, R M Merion, P B Watkins.   

Abstract

CYP3A4, a major Phase I xenobiotic metabolizing enzyme present in liver, is also present in human small bowel epithelium where it appears to catalyse significant 'first pass' metabolism of some drugs. To determine whether CYP3A4 or the related enzymes CYP3A3, CYP3A5, and CYP3A7 are present in other regions of the digestive tract, we used CYP3A-specific antibodies to examine histological sections and epithelial microsomes obtained from a human organ donor. CYP3A-related proteins were detected in epithelia throughout the digestive tract and in gastric parietal cells, in pericentral hepatocytes, and in ductular cells of the pancreas. Immunoblot analysis suggested that the major CYP3A protein present in liver, jejunum, colon, and pancreas was CYP3A4 or CYP3A3, whereas CYP3A5 was the major protein present in stomach. Both CYP3A4 and CYP3A5 mRNA were detectable in all regions of the digestive tract using the polymerase chain reaction (PCR); however, only CYP3A4 could be detected by Northern blot analysis. CYP3A7 mRNA was consistently detected only in the liver by PCR and CYP3A3 mRNA was not detected in any of the tissues. We conclude that CYP3A4 and CYP3A5 are present throughout the human digestive tract and that differences in the expression of these enzymes may account for inter-organ differences in the metabolism of CYP3A substrates.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7894497     DOI: 10.1097/00008571-199410000-00003

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  73 in total

1.  The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function.

Authors:  G Everson; K C Lasseter; K E Anderson; L A Bauer; R L Carithens; K D Wilner; A Johnson; R J Anziano; T A Smolarek; R Z Turncliff
Journal:  Br J Clin Pharmacol       Date:  2000       Impact factor: 4.335

2.  Increased cytotoxicity of food-borne mycotoxins toward human cell lines in vitro via enhanced cytochrome p450 expression using the MTT bioassay.

Authors:  C W Lewis; J E Smith; J G Anderson; R I Freshney
Journal:  Mycopathologia       Date:  1999-11       Impact factor: 2.574

3.  Cytochromes P450 are expressed in proliferating cells in Barrett's metaplasia.

Authors:  S J Hughes; M A Morse; C M Weghorst; H Kim; P B Watkins; F P Guengerich; M B Orringer; D G Beer
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

Review 4.  The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.

Authors:  H A Bardelmeijer; O van Tellingen; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

Review 5.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

Review 6.  Dietary effects on drug metabolism and transport.

Authors:  Robert Z Harris; Graham R Jang; Shirley Tsunoda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 7.  Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes.

Authors:  Adam S Darwich; Kathryn Henderson; Angela Burgin; Nicola Ward; Janet Whittam; Basil J Ammori; Darren M Ashcroft; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

8.  Drug-drug interaction pattern recognition.

Authors:  John Z Duan
Journal:  Drugs R D       Date:  2010

Review 9.  [Effect of intestinal cytochrome P450 3A on phytochemical presystemic metabolism].

Authors:  Fang Xia; Xiao-yin Chen
Journal:  Chin J Integr Med       Date:  2005-09       Impact factor: 1.978

Review 10.  Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model.

Authors:  Xianhua Cao; Seth T Gibbs; Lanyan Fang; Heather A Miller; Christopher P Landowski; Ho-Chul Shin; Hans Lennernas; Yanqiang Zhong; Gordon L Amidon; Lawrence X Yu; Duxin Sun
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.